Clinical outcomes of allogeneic hematopoietic stem cell transplant with different stem cell sources in infant acute myeloid leukemia
Abstract Acute Myeloid Leukemia (AML) in infants constitutes a rare and biologically distinct subgroup. Hematopoietic stem cell transplantation (HSCT) plays a pivotal role in the treatment of infant AML. However, the source of stem cells remains insufficiently explored. This study aimed to evaluate...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-05602-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849763741267132416 |
|---|---|
| author | Yuyang Wang Yibing Guo Xiuxin Ling Junhui Li Tao Hu Zhaoxia Zhang Mengze Hu Zeliang Song Mei Yue Ruihong Tang Dixiao Zhong Rong Liu |
| author_facet | Yuyang Wang Yibing Guo Xiuxin Ling Junhui Li Tao Hu Zhaoxia Zhang Mengze Hu Zeliang Song Mei Yue Ruihong Tang Dixiao Zhong Rong Liu |
| author_sort | Yuyang Wang |
| collection | DOAJ |
| description | Abstract Acute Myeloid Leukemia (AML) in infants constitutes a rare and biologically distinct subgroup. Hematopoietic stem cell transplantation (HSCT) plays a pivotal role in the treatment of infant AML. However, the source of stem cells remains insufficiently explored. This study aimed to evaluate the clinical outcomes of allogeneic HSCT from different sources. We conducted a single-center retrospective analysis of 27 infants with AML who underwent HSCT. We compared peripheral blood (PB) with/without bone marrow (BM) (Group 1, n = 16) versus umbilical cord blood (UCB) (Group 2, n = 12). There was no significant difference in 3-year overall survival (OS), disease-free survival (DFS), 3-year recurrence rates, or one-year cumulative graft-versus-host disease (GVHD) incidence between two groups (3-year OS: 80.36% for group 1 vs. 91.67% for group 2, p = 0.5474; DFS: 73.66% vs. 69.84%, p = 0.8232; GVHD: 56.25% for group 1 vs. 50.0% for group 2, p = 0.824). The group with pre-transplant minimal residual disease (MRD) status had a lower recurrence rate. This study emphasizes the efficacy of HSCT in the treatment of infant AML, with higher OS rates compared to childhood AML. It also supports UCB as a viable stem cell source. Achieving MRD-negative status before transplantation is crucial for improving post-transplant outcomes. |
| format | Article |
| id | doaj-art-c0a6ce9fb58042b68c797c3f8568f4de |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-c0a6ce9fb58042b68c797c3f8568f4de2025-08-20T03:05:18ZengNature PortfolioScientific Reports2045-23222025-07-011511910.1038/s41598-025-05602-zClinical outcomes of allogeneic hematopoietic stem cell transplant with different stem cell sources in infant acute myeloid leukemiaYuyang Wang0Yibing Guo1Xiuxin Ling2Junhui Li3Tao Hu4Zhaoxia Zhang5Mengze Hu6Zeliang Song7Mei Yue8Ruihong Tang9Dixiao Zhong10Rong Liu11Department of Hematology, Capital Center for Children’s Health, Capital Medical UniversityBioengineeringBioengineeringDepartment of Hematology, Capital Center for Children’s Health, Capital Medical UniversityDepartment of Hematology, Capital Center for Children’s Health, Capital Medical UniversityDepartment of Hematology, Capital Center for Children’s Health, Capital Medical UniversityDepartment of Hematology, Capital Center for Children’s Health, Capital Medical UniversityDepartment of Hematology, Capital Center for Children’s Health, Capital Medical UniversityDepartment of Hematology, Capital Center for Children’s Health, Capital Medical UniversityDepartment of Hematology, Capital Center for Children’s Health, Capital Medical UniversityDepartment of Hematology, Capital Center for Children’s Health, Capital Medical UniversityDepartment of Hematology, Capital Center for Children’s Health, Capital Medical UniversityAbstract Acute Myeloid Leukemia (AML) in infants constitutes a rare and biologically distinct subgroup. Hematopoietic stem cell transplantation (HSCT) plays a pivotal role in the treatment of infant AML. However, the source of stem cells remains insufficiently explored. This study aimed to evaluate the clinical outcomes of allogeneic HSCT from different sources. We conducted a single-center retrospective analysis of 27 infants with AML who underwent HSCT. We compared peripheral blood (PB) with/without bone marrow (BM) (Group 1, n = 16) versus umbilical cord blood (UCB) (Group 2, n = 12). There was no significant difference in 3-year overall survival (OS), disease-free survival (DFS), 3-year recurrence rates, or one-year cumulative graft-versus-host disease (GVHD) incidence between two groups (3-year OS: 80.36% for group 1 vs. 91.67% for group 2, p = 0.5474; DFS: 73.66% vs. 69.84%, p = 0.8232; GVHD: 56.25% for group 1 vs. 50.0% for group 2, p = 0.824). The group with pre-transplant minimal residual disease (MRD) status had a lower recurrence rate. This study emphasizes the efficacy of HSCT in the treatment of infant AML, with higher OS rates compared to childhood AML. It also supports UCB as a viable stem cell source. Achieving MRD-negative status before transplantation is crucial for improving post-transplant outcomes.https://doi.org/10.1038/s41598-025-05602-zHematopoietic stem cell transplantationAcute myeloid leukemiaSurvivalRecurrence rates |
| spellingShingle | Yuyang Wang Yibing Guo Xiuxin Ling Junhui Li Tao Hu Zhaoxia Zhang Mengze Hu Zeliang Song Mei Yue Ruihong Tang Dixiao Zhong Rong Liu Clinical outcomes of allogeneic hematopoietic stem cell transplant with different stem cell sources in infant acute myeloid leukemia Scientific Reports Hematopoietic stem cell transplantation Acute myeloid leukemia Survival Recurrence rates |
| title | Clinical outcomes of allogeneic hematopoietic stem cell transplant with different stem cell sources in infant acute myeloid leukemia |
| title_full | Clinical outcomes of allogeneic hematopoietic stem cell transplant with different stem cell sources in infant acute myeloid leukemia |
| title_fullStr | Clinical outcomes of allogeneic hematopoietic stem cell transplant with different stem cell sources in infant acute myeloid leukemia |
| title_full_unstemmed | Clinical outcomes of allogeneic hematopoietic stem cell transplant with different stem cell sources in infant acute myeloid leukemia |
| title_short | Clinical outcomes of allogeneic hematopoietic stem cell transplant with different stem cell sources in infant acute myeloid leukemia |
| title_sort | clinical outcomes of allogeneic hematopoietic stem cell transplant with different stem cell sources in infant acute myeloid leukemia |
| topic | Hematopoietic stem cell transplantation Acute myeloid leukemia Survival Recurrence rates |
| url | https://doi.org/10.1038/s41598-025-05602-z |
| work_keys_str_mv | AT yuyangwang clinicaloutcomesofallogeneichematopoieticstemcelltransplantwithdifferentstemcellsourcesininfantacutemyeloidleukemia AT yibingguo clinicaloutcomesofallogeneichematopoieticstemcelltransplantwithdifferentstemcellsourcesininfantacutemyeloidleukemia AT xiuxinling clinicaloutcomesofallogeneichematopoieticstemcelltransplantwithdifferentstemcellsourcesininfantacutemyeloidleukemia AT junhuili clinicaloutcomesofallogeneichematopoieticstemcelltransplantwithdifferentstemcellsourcesininfantacutemyeloidleukemia AT taohu clinicaloutcomesofallogeneichematopoieticstemcelltransplantwithdifferentstemcellsourcesininfantacutemyeloidleukemia AT zhaoxiazhang clinicaloutcomesofallogeneichematopoieticstemcelltransplantwithdifferentstemcellsourcesininfantacutemyeloidleukemia AT mengzehu clinicaloutcomesofallogeneichematopoieticstemcelltransplantwithdifferentstemcellsourcesininfantacutemyeloidleukemia AT zeliangsong clinicaloutcomesofallogeneichematopoieticstemcelltransplantwithdifferentstemcellsourcesininfantacutemyeloidleukemia AT meiyue clinicaloutcomesofallogeneichematopoieticstemcelltransplantwithdifferentstemcellsourcesininfantacutemyeloidleukemia AT ruihongtang clinicaloutcomesofallogeneichematopoieticstemcelltransplantwithdifferentstemcellsourcesininfantacutemyeloidleukemia AT dixiaozhong clinicaloutcomesofallogeneichematopoieticstemcelltransplantwithdifferentstemcellsourcesininfantacutemyeloidleukemia AT rongliu clinicaloutcomesofallogeneichematopoieticstemcelltransplantwithdifferentstemcellsourcesininfantacutemyeloidleukemia |